Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021)
Recursion Pharmaceuticals (RXRX) posted Income from Non-Controlling Interests of $43.4 million for Q2 2021, up 241.29% on a QoQ basis from -$30.7 million in Q1 2021, and up 129.11% year-over-year from $18.9 million in Q2 2020.
Recursion Pharmaceuticals (RXRX) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $43.4 million for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 43.40 Mn |
| Mar 31, 2021 | -30.72 Mn |
| Jun 30, 2020 | 18.94 Mn |
| Mar 31, 2020 | -18.42 Mn |